Logo image of TLSI

TRISALUS LIFE SCIENCES INC (TLSI) Stock Fundamental Analysis

NASDAQ:TLSI - US89680M1018 - Common Stock

4.99 USD
0 (0%)
Last: 9/8/2025, 12:16:41 PM
Fundamental Rating

2

Taking everything into account, TLSI scores 2 out of 10 in our fundamental rating. TLSI was compared to 541 industry peers in the Biotechnology industry. Both the profitability and financial health of TLSI have multiple concerns. TLSI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TLSI had negative earnings in the past year.
TLSI had a negative operating cash flow in the past year.
In multiple years TLSI reported negative net income over the last 5 years.
TLSI had a negative operating cash flow in each of the past 5 years.
TLSI Yearly Net Income VS EBIT VS OCF VS FCFTLSI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -82.73%, TLSI is doing worse than 70.06% of the companies in the same industry.
Industry RankSector Rank
ROA -82.73%
ROE N/A
ROIC N/A
ROA(3y)-123.26%
ROA(5y)-73.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TLSI Yearly ROA, ROE, ROICTLSI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

The Gross Margin of TLSI (84.67%) is better than 87.43% of its industry peers.
TLSI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.67%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLSI Yearly Profit, Operating, Gross MarginsTLSI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

TLSI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TLSI has been increased compared to 1 year ago.
Compared to 1 year ago, TLSI has a worse debt to assets ratio.
TLSI Yearly Shares OutstandingTLSI Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
TLSI Yearly Total Debt VS Total AssetsTLSI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -8.41, we must say that TLSI is in the distress zone and has some risk of bankruptcy.
TLSI's Altman-Z score of -8.41 is on the low side compared to the rest of the industry. TLSI is outperformed by 69.50% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.41
ROIC/WACCN/A
WACC9.59%
TLSI Yearly LT Debt VS Equity VS FCFTLSI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 4.08 indicates that TLSI has no problem at all paying its short term obligations.
The Current ratio of TLSI (4.08) is comparable to the rest of the industry.
TLSI has a Quick Ratio of 3.68. This indicates that TLSI is financially healthy and has no problem in meeting its short term obligations.
TLSI has a Quick ratio (3.68) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.08
Quick Ratio 3.68
TLSI Yearly Current Assets VS Current LiabilitesTLSI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 47.17% over the past year.
TLSI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.38%.
EPS 1Y (TTM)47.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)15.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%52.27%

3.2 Future

TLSI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.74% yearly.
TLSI is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.57% yearly.
EPS Next Y38.54%
EPS Next 2Y38.23%
EPS Next 3Y29.74%
EPS Next 5YN/A
Revenue Next Year54.55%
Revenue Next 2Y54.35%
Revenue Next 3Y50.5%
Revenue Next 5Y42.57%

3.3 Evolution

TLSI Yearly Revenue VS EstimatesTLSI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
TLSI Yearly EPS VS EstimatesTLSI Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

TLSI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLSI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLSI Price Earnings VS Forward Price EarningsTLSI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLSI Per share dataTLSI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as TLSI's earnings are expected to grow with 29.74% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.23%
EPS Next 3Y29.74%

More info and screens

0

5. Dividend

5.1 Amount

TLSI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRISALUS LIFE SCIENCES INC

NASDAQ:TLSI (9/8/2025, 12:16:41 PM)

4.99

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-11 2025-11-11
Inst Owners8.15%
Inst Owner Change188.15%
Ins Owners20.45%
Ins Owner Change3.47%
Market Cap248.85M
Analysts82.86
Price Target11.54 (131.26%)
Short Float %1.88%
Short Ratio4.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-47.45%
Min EPS beat(2)-73.8%
Max EPS beat(2)-21.11%
EPS beat(4)1
Avg EPS beat(4)-13.12%
Min EPS beat(4)-73.8%
Max EPS beat(4)66%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.14%
Min Revenue beat(2)-0.53%
Max Revenue beat(2)2.81%
Revenue beat(4)1
Avg Revenue beat(4)-0.12%
Min Revenue beat(4)-2.55%
Max Revenue beat(4)2.81%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.09%
EPS NQ rev (1m)13.99%
EPS NQ rev (3m)-11.81%
EPS NY rev (1m)5.24%
EPS NY rev (3m)-32.94%
Revenue NQ rev (1m)0.54%
Revenue NQ rev (3m)0.29%
Revenue NY rev (1m)0.9%
Revenue NY rev (3m)1.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.91
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-0.12
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.57
OCFYN/A
SpS0.72
BVpS-0.39
TBVpS-0.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.73%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.67%
FCFM N/A
ROA(3y)-123.26%
ROA(5y)-73.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 125.89%
Cap/Sales 2.45%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.08
Quick Ratio 3.68
Altman-Z -8.41
F-Score3
WACC9.59%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)47.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y38.54%
EPS Next 2Y38.23%
EPS Next 3Y29.74%
EPS Next 5YN/A
Revenue 1Y (TTM)15.38%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%52.27%
Revenue Next Year54.55%
Revenue Next 2Y54.35%
Revenue Next 3Y50.5%
Revenue Next 5Y42.57%
EBIT growth 1Y51.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year63.19%
EBIT Next 3Y32.17%
EBIT Next 5Y25.95%
FCF growth 1Y-36.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.84%
OCF growth 3YN/A
OCF growth 5YN/A